Compare First Trust Cloud Computing ETF (SKYY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? First Trust Cloud Computing ETF trades at $164 (market cap $3.57B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SKYY | TVTX | |
|---|---|---|
Market Cap | $3.57B | $5.02B |
Volume | 236,993 | 2,060,842 |
52-Week High | $174.89 | $67.52 |
52-Week Low | $104.16 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY, the First Trust Cloud Computing ETF, trades at $171.52, down 0.57% today but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though RSI suggests mild overbought conditions. The ETF provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights institutional adjustments and positive coverage on cloud infrastructure growth.
The outlook for SKYY is positive, driven by secular trends in cloud computing and AI. Investment opportunities include sector growth and diversification benefits, while risks involve market volatility and sector-specific competition. The ETF's performance hinges on continued tech infrastructure spending and macroeconomic conditions affecting tech stocks.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
